# BMI Global Health

# Prevalence of non-communicable disease risk factors in three sites across Papua New Guinea: a cross-sectional study

Patricia Rarau,<sup>1,2</sup> Gwendalyn Vengiau,<sup>2,3</sup> Hebe Gouda,<sup>2,3,4</sup> Suparat Phuanukoonon,<sup>2,5</sup> Isi H Kevau,<sup>6</sup> Chris Bullen,<sup>7</sup> Robert Scragg,<sup>7</sup> Ian Riley,<sup>1,3</sup> Geoffrey Marks,<sup>3</sup> Masahiro Umezaki,<sup>8</sup> Ayako Morita,<sup>9</sup> Brian Oldenburg,<sup>1</sup> Barbara McPake,<sup>10</sup> Justin Pulford<sup>2,11</sup>

**To cite:** Rarau P, Vengiau G, Gouda H, *et al.* Prevalence of non-communicable disease risk factors in three sites across Papua New Guinea: a crosssectional study. *BMJ Glob Health* 2017;**2**:e000221. doi:10.1136/ bmjgh-2016-000221

Received 23 October 2016 Revised 21 February 2017 Accepted 13 March 2017

# **ABSTRACT**

Papua New Guinea (PNG) is a culturally, environmentally and ethnically diverse country of 7.3 million people experiencing rapid economic development and social change. Such development is typically associated with an increase in non-communicable disease (NCD) risk factors. Aim To establish the prevalence of NCD risk factors in three different regions across PNG in order to guide appropriate prevention and control measures.

**Methods** A cross-sectional survey was undertaken with randomly selected adults (15–65 years), stratified by age and sex recruited from the general population of integrated Health and Demographic Surveillance Sites in West Hiri (periurban), Asaro (rural highland) and Karkar Island (rural island), PNG. A modified WHO STEPS risk factor survey was administered along with anthropometric and biochemical measures on study participants.

Results The prevalence of NCD risk factors was markedly different across the three sites. For example, the prevalences of current alcohol consumption at 43% (95% Cl 35 to 52), stress at 46% (95% Cl 40 to 52), obesity at 22% (95% Cl 18 to 28), hypertension at 22% (95% Cl 17 to 28), elevated levels of cholesterol at 24% (95% Cl 19 to 29) and haemoglobin A1c at 34% (95% Cl 29 to 41) were highest in West Hiri relative to the rural areas. However, central obesity at 90% (95% Cl 86 to 93) and prehypertension at 55% (95% Cl 42 to 62) were most common in Asaro whereas prevalences of smoking, physical inactivity and low high-density lipoprotein-cholesterol levels at 52% (95% Cl 45 to 59), 34% (95% Cl 26 to 42) and 62% (95% Cl 56 to 68), respectively, were highest in Karkar Island.

**Conclusion** Adult residents in the three different communities are at high risk of developing NCDs, especially the West Hiri periurban population. There is an urgent need for appropriate multisectoral preventive interventions and improved health services. Improved monitoring and control of NCD risk factors is also needed in all regions across PNG.



For numbered affiliations see end of article.

Correspondence to Dr Patricia Rarau; prarau@student.unimelb.edu.au

### INTRODUCTION

Non-communicable diseases (NCDs) are the leading cause of death and morbidity

# **Key questions**

# What is already known about this topic?

- ➤ The prevalence of non-communicable diseases (NCDs) and their risk factors in Papua New Guinea is increasing but varied based on ethnicity, lifestyle and the living environment.
- ► Current prevalence of NCD and their risk factors is unknown in West Hiri, a community impacted by a gas mining project and two rural non-project impact areas, Asaro and Karkar Island.

# What are the new findings?

- Our study provided a baseline prevalence of NCD risk factors in West Hiri and an up-to-date prevalence of NCD risk factors in Asaro and Karkar Island.
- ► Results suggest that socioeconomic and nutrition transition may be under way in all sites but more apparent in the West Hiri population.

# **Recommendations for policy**

► The results strongly suggest an introduction of control measures particularly in West Hiri and continuous monitoring across the country.

throughout the world, with the greatest burden in low and middle-income countries (LMICs), where nearly 80% of NCD-related deaths and 82% of all NCD premature deaths occur. According to the WHO, approximately 46% of all NCD-related deaths in 2012 were due to cardiovascular diseases (CVDs), followed by cancers (22%), respiratory disease (11%) and diabetes (4%). Furthermore, the global burden of diseases study reported that CVDs, such as ischaemic heart disease and stroke, continue to be among the top three leading causes of death globally.

Papua New Guinea (PNG) is a country of approximately 7.3 million people located in the Western Pacific and renowned for its





environmental, cultural and biological diversity. 45 PNG is categorised as a lower-middle-income country according to the World Bank criteria and is experiencing rapid economic growth as a result of large-scale mineral and gas resource developments.<sup>7</sup> Rapid economic growth in other LMICs has been associated with an epidemiological transition characterised by an increasing prevalence of NCDs and their risk factors with an often concomitant reduction in infectious disease. 89 While infectious diseases such as acute respiratory tract infections, tuberculosis, malaria and HIV/AIDS are the leading causes of morbidity and mortality in PNG, 10 the available evidence suggests this pattern is changing among those adult populations with longer exposure to modernisation. The latter is leading to rapid lifestyle changes associated with increases in CVD and diabetes. <sup>11–23</sup> In addition, PNG still has high rates of child-hood stunting, <sup>24–26</sup> a risk factor for NCDs in adulthood. <sup>27</sup> The cost of treating and managing a growing NCD burden is already posing a substantial challenge to the country's economy, particularly given the challenges of the PNG health system, which include deteriorating infrastructure, poor governance, an ageing and inadequate healthcare workforce, and a paucity of specialist services.<sup>28</sup>

NCDs and associated risk factors, such as smoking, excessive alcohol consumption, stress, unhealthy diet, physical inactivity, obesity, hypertension and abnormal lipid profiles, have not been well investigated in PNG. Several small studies conducted among specific populations over the past few decades have identified an increasing, or relatively high, prevalence of NCDs and NCD risk factors. 18 19 21 29-34 They suggest variations in NCD risks within PNG based on lifestyle and living environment 18 19 21 29 and on ethnic origin. 33 34 Furthermore, a lack of physical activity, particularly among urban migrants, increases the risk of acquiring an NCD<sup>19 21</sup>; and urban dwellers of any ethnic origin in PNG are at higher risk of CVDs and diabetes relative to their rural peers. 19 21 31 32 35 The 2007/2008 PNG NCD Risk Factor STEPS study reported that the majority of surveyed adults were at risk of developing NCDs. 36 Since the STEPS survey, there has been limited up-to-date information on the prevalence of NCD risk factors across the diverse populations of PNG. Major resource developments have occurred since the STEPS survey last decade, and there is a need for a comprehensive NCD risk survey during this period of development. Currently in PNG, there is no systematic monitoring of NCD prevalence, or the associated risk factors, to measure the anticipated epidemiological transition across the country.

The present study was undertaken during the construction phase of a large-scale gas development which was projected to more than double the gross domestic product of PNG. Our study was designed to provide baseline prevalence data on NCD risk factors in the initial years of a gas project impact site (West Hiri) and in two non-project impact sites (Asaro and Karkar). It was also anticipated that the study findings would provide up-to-date NCD prevalence data to help the national government plan

services and develop cost-effective interventions. In this paper, we describe the methods used and present the initial findings for NCD risk factors in a survey of three different sociodemographic populations of PNG.

# **METHODS**

# Study design


Between April 2013 and October 2014, we undertook a cross-sectional, community-based survey in three integrated Health and Demography Surveillance Sites (iHDSS) set up by the PNG Institute of Medical Research (PNGIMR).<sup>37</sup> <sup>38</sup> The study included the completion of a standardised questionnaire based on the WHO STEPwise approach for NCD Risk Factor surveillance, which included physical measurements and biological sample collection from randomly selected adults (aged 15–65 years) from the general population of each iHDSS. Information on health service utilisation was not collected but can be incorporated and reported in future NCD risk factor surveys and analysis. Further cross-sectional surveys of NCD risk factors and prevalence are planned for each iHDSS in the future, pending additional funding.

# Sample size and selection

Using a simple random sampling procedure, a total of 300 adult participants, stratified by sex and age (15–29, 30–44, 45–65 years), were sought from each iHDSS (ie, 100 participants from each of the three age groups, 50 male and 50 female) and invited to take part in the study. The sampling frame was a full population census of the adult general population of each iHDSS. The target sample size (n=900) was estimated to confer 80% power to detect a 10% absolute difference in the proportion of most risk factors for all ages combined between each site or a 10% relative difference in means at the 0.05 significance level (two sided).

# **Study sites**

The three iHDSS were West Hiri (Central Province), Asaro (Eastern Highlands Province) and Karkar Island (Madang Province) as shown in figure 1. The West Hiri iHDSS comprises villages with a baseline (2011) population of 11531 people<sup>37</sup> of Austronesian ancestry, <sup>40</sup> distributed along a 20-30 km stretch of coastline northwest of Port Moresby, the national capital and largest city in PNG. The West Hiri site was selected because it represents a periurban population affected by a large gas development project. The villages surround a gas processing plant and their close proximity to Port Moresby has changed the traditional diet, social cohesion and skilled activities such as fishing and gardening.<sup>41</sup> The Asaro iHDSS comprises a baseline (2011) population of 10034 people<sup>37 38</sup> of non-Austronesian ancestry,<sup>40</sup> situated 40-45 km north-east of Goroka, the largest town in the Eastern highlands. People in Asaro are primarily subsistence farmers, but earn cash through smallholder production of coffee, employment on plantations and selling garden produce. 42 The Karkar Island



**Figure 1** Map of Papua New Guinea showing the three survey sites: West Hiri (periurban) and two rural communities, Asaro and Karkar Island.

iHDSS comprises a rural baseline population of 18623 people<sup>37 38</sup> of both Austronesian and non-Austronesian ancestries<sup>43</sup> located 30 km off the northern coastline of Madang Province. Most adult residents of Karkar Island are subsistence farmers and/or unskilled labourers. The island's soil is fertile and large plantations produce the island's main exports of cocoa and coconut and provide most of the local employment opportunities.<sup>37 38</sup> The majority of PNG's population live in rural areas and about 87% of the adult population is engaged in both subsistence farming and commercial activities.<sup>5 44</sup> Therefore, Asaro and Karkar Island populations reflect rural communities that largely depend on subsistence farming and cash cropping in highlands and lowlands/coastal PNG, respectively.

# Study measures and collection methods

Interviews were conducted at participants' homes or community health facilities. Eligibility criteria included recorded residence within the respective iHDSS and ages between 15 and 65 years at the time of survey. Women were excluded if they were pregnant at the time of recruitment. All survey forms and procedures were completed at a single time point by the survey team.

# Interviews

The NCD study tool was adapted from the WHO STEPS NCD Risk Factor Survey. <sup>39</sup> Question domains included: participant demographics; self-reported health status; self-reported stress; consumption of vegetables, fruits, protein, fried food, salt and sugar; food security; tobacco, betel nut and alcohol use; physical activity; participant history of NCD and/or associated treatments. The self-reported stress, diet and physical activity questions were all developed specifically for this study and for use with PNG-based populations. The questionnaire was available in English and *Tok Pisin*, the local creole language that

the interviewers could speak fluently. All questionnaires were piloted extensively prior to survey commencement.

### Measurement

Weight in kilograms (kg) was measured using a Seca digital scale to 100 g precision and height (cm) to 0.1 cm precision using a Seca Leicester stadiometer. Participants were able to wear light clothes, but no shoes. A Seca figure finder constant tension tape was used to measure to 0.1 cm precision the hip (level of widest part of the buttocks) and waist circumferences (midpoint between lower rib and iliac crest) in centimetre (cm). After participants had rested for 10 min in a sitting position their blood pressures (BP) were measured using an OMRON T9P digital automated sphygmomanometer. Three readings were taken at 1 min intervals using appropriate cuff sizes and the average of the three readings was used for the analysis.

# **Biochemical measures**

Capillary blood from a finger prick was taken on the spot and analysed for haemoglobin levels using a HemoCue device (HemoCue Hb201<sup>+</sup>, Angelholm, Sweden). If haemoglobin levels were above 6g/dL, a further 30 mL of non-fasting venous blood was collected. The initial 10 mL of blood was collected using EDTA vacutainers and analysed for haemoglobin A1c (HbA1c) levels using the DCA Vantage Analyzer from Siemens Healthcare Australia and New Zealand. The remaining 20 mL was collected using two 10 mL serum vacutainers which were aliquoted and stored initially at -20°C in each study site before they were transported to the Port Moresby PNGIMR laboratory. The serum samples were analysed for lipids (cholesterol and high-density lipoprotein-cholesterol (HDL-C)) using Vitros 250/350 Biochemistry System from Ortho Clinical Diagnostics, in batches within a month of collection. After analysis, aliquots of plasma, serum and cell pallets were stored initially at −20°C freezer in Port Moresby before archiving in −80°C freezer for long-term storage.

# Measurement of NCD risk factors

Daily tobacco smoking was defined as current tobacco smoking on a daily basis and current alcohol consumption was defined as alcohol consumption within the last 30 days. Betel nut chewing which consists of areca nut, betel leaf/bean and slaked lime is widely practised across PNG and current use was defined as betel nut chewing within the last 30 days. Insufficient physical activity was defined as spending less than 75 or 150 min/week on vigorous and moderate physical activities, respectively. 45 Body mass index (BMI) was calculated as weight (kg) divided by height in metres squared (m<sup>2</sup>). Overweight and obesity were defined as BMI ≥25-29.9 kg/ m<sup>2</sup> and ≥30 kg/m<sup>2</sup>, respectively. <sup>46</sup> Central obesity in men and women was defined as a waist-to-hip ratio ≥0.90 and ≥0.85 for men and women, respectively.<sup>47</sup> Hypertension was defined as the average of the three systolic and/or diastolic BP readings of ≥140 mm Hg and/or ≥90 mm



Hg, respectively or diagnosed hypertensive cases on antihypertensive drugs. <sup>48</sup> Prehypertension was defined as systolic and diastolic BPs of >120–139.9 mm Hg and >80–89.9 mm Hg, respectively. <sup>48</sup> Elevated cholesterol levels were defined as cholesterol levels of >6.2 mm/L. Low HDL-C levels were defined as <1 mmol/L and <1.3 mmol/L for men and women, respectively. <sup>49</sup> <sup>50</sup> Participants with elevated HbA1c were defined to have HbA1c levels  $\geq$ 5.7%. In accordance with the American Diabetes Association Standards of Medical Care in Diabetes, diabetes mellitus type 2 (DMT2) was diagnosed if the participant was on antidiabetic drugs or when the participants' HbA1c was  $\geq$ 6.5%. <sup>51</sup>

# **Data analysis**

STATA/SE V.13.0 (StataCorp LP) was used for all data analyses. Analysis was limited to descriptive summaries of all major measures and inferential analyses to assess intersite differences for major outcome variables using Pearson's  $\chi^2$  test, Fisher's exact test and one-way analysis of variance where appropriate. Risk factor prevalence with 95% CI for binary variables and the means with SD for continuous variables were examined by study site. More detailed analyses exploring relationships between specified risk factors and NCDs as well as lung function, haemoglobin and urine microalbumin levels, detailed dietary and physical activity results will be presented in subsequent publications. The totals (No.) presented in all tables are denominators unless otherwise stated. Tobacco, betel nut and alcohol questions were not originally included in the NCD questionnaire, and as a result, these questions were not asked of all participants. To address missing values, available case analysis was used.

# **Ethics approval**

The study was given ethical approval by the PNGIMR Institutional Review Board (IRB) and the PNG Medical Research Advisory Committee (MRAC) (IRB No. 1208, 23 March 2012; MRAC No. 12.34, November 2012). Written, informed consent was obtained prior to study participation. Any participant identified with hypertension, DMT2, hyperlipidaemia or chronic obstructive pulmonary disease was referred to the local general hospital for further investigation and management.

# **RESULTS**

Of the total 900 randomly selected participants, 785 (87.2%) adults participated in the survey. Here we present the results of the 772 participants who completed the survey and had their blood collected. Table 1 presents the demographic characteristics of the overall study population and by iHDSS. The three study sites were comparable in terms of participants' age and sex. Overall, 33% of study participants received an education past primary school level and only 16% were engaged in paid employment. Across the sites, West Hiri participants were better educated and more likely to be in paid employment compared with participants from Asaro and Karkar

Island, where the majority were subsistence farmers/cash croppers.

Participants were asked about their weekly consumption of vegetables, fruits, protein, sugar, salt and fried food. As shown in table 2, 65% and 58% of all participants reported the consumption of root and green vegetables, respectively, for at least 5 days of the week but this varied across sites (p<0.001). Residents of West Hiri reported the lowest percentage of root vegetable (17%) and greens (14%) consumption; however, they reported the highest percentage of fruit (24%) and animal protein (canned 52% and fresh 48%) consumption. The addition of at least 6 teaspoons of sugar in a hot drink daily was highest in both Asaro (20%) and West Hiri (20%) compared with Karkar Island (11%) (p<0.03). Fried food consumption also varied across the sites with Asaro participants (43%) recording the highest consumption of fried food at home, 5 or more days per week, relative to West Hiri (16%) and Karkar Island (0%) (p<0.001). The lowest salt consumption was reported by Karkar Island participants (22%) compared with those in West Hiri and Asaro.

Participants were asked if a health worker had previously diagnosed them with one or more of a range of specified NCDs. Overall, as shown in table 3, very few participants reported having received a diagnosis of any of the stated conditions and all diagnoses, except hypertension, chronic lung disease and cancer, were from West Hiri. Participants from Karkar and Asaro reported the least number of NCD diagnoses.

Table 4 presents data on behavioural and clinical NCD risk factors. Tobacco smoking was common across all three sites but we found significant differences between the sites in the type of tobacco smoked. West Hiri participants only smoked manufactured tobacco, but Karkar Island and Asaro reported higher prevalence of smoking home-grown tobacco as compared with manufactured tobacco. Prevalence of betel nut use was also high across all three sites, although current alcohol consumption was comparatively lower, especially in Karkar Island (7%). Higher proportions of men than women smoked tobacco and drank alcohol. Overall, 32% of participants reported currently feeling stressed. The prevalence of stress was significantly higher in West Hiri and Asaro compared with Karkar Island (p<0.001). The prevalence of insufficient physical activity was highest in Karkar Island (34%) compared with Asaro (6%) and West Hiri (23%) (p<0.001). Overall, 19% and 11% of participants were categorised as overweight or obese, respectively. There was a statistically significant difference between the sites with higher prevalence of overweight (25%) and obesity (22%) in West Hiri compared with the other two sites (p<0.001). However, Asaro had a higher percentage (90%) of participants with central obesity, based on the waist-to-hip ratio, than the other two sites and this difference was statistically significant (p<0.001). There was also a statistically significant difference in the prevalence of hypertension between the sites, with Karkar Island



**Table 1** Demographic characteristics of the participants of the non-communicable disease study by iHDSS. The values are numbers and percentages (95% CI)

	Overa		West (n=26		Asar (n=2	-	Kark (n=2	ar Island 52)
	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
Sex								
Male	361	47 (43 to 50)	114	43 (37 to 49)	130	51 (45 to 58)	117	46 (40 to 53)
Female	411	53 (50 to 57)	152	57 (51 to 63)	124	49 (43 to 55)	135	54 (48 to 60
Age group (years)								
15–29	216	28 (25 to 31)	73	27 (22 to 33)	69	27 (22 to 33)	74	29 (24 to 35)
30–44	261	34 (31 to 37)	93	35 (29 to 41)	88	35 (29 to 41)	30	32 (8 to 17)
45–65	295	38 (35 to 42)	100	38 (32 to 44)	97	38 (32 to 45)	98	39 (33 to 45)
Education								
Primary or lower	519	67 (64 71)	119	45 (39 to 51)	198	78 (72 to 83)	202	80 (75 to 85)
Some/complete secondary	159	21 (18 to 24)	92	35 (29 to 41)	28	11 (8 to 16)	39	16 (11 to 21)
Vocational/tertiary	26	3 (2 to 5)	20	8 (5 to 11)	3	1 (0 to 3)	3	1 (0 to 3)
Don't know	68	9 (7 to 11)	35	13 (9 to 18)	25	10 (7 to 14)	8	3 (1 to 6)
Employment								
Home duties	157	20 (18 to 23)	92	35 (29 to 41)	15	6 (3 to 10)	50	20 (15 to 25)
Subsistence/cash cropper	349	45 (42 to 49)	23	9 (6 to 13)	179	71 (64 to 76)	147	58 (52 to 65)
Paid employment	121	16 (13 to 18)	89	34 (28 to 40)	15	6 (3 to 10)	17	7 (4 to 11)
Unemployed/retired/student	114	15 (12 to 18)	55	21 (16 to 26)	24	10 (6 to 14)	35	14 (10 to 19)
Not given	31	4 (3 to 6)	7	3 (1 to 5)	21	8 (5 to 12)	3	1 (0 to 3)
Marital status								
Single/never married	155	20 (17 to 23)	62	23 (18 to 29)	38	15 (11 to 20)	55	22 (17 to 27)
Married	508	66 (62 to 29)	167	63 (57 to 69)	157	62 (56 to 68)	184	73 (67 to 78)
Separated/divorced	33	4 (3 to 6)	6	2 (1 to 5)	22	9 (6 to 13)	5	2 (1 to 5)
Widowed	33	4 (3 to 6)	14	5 (3 to 9)	14	6 (3 to 9)	5	2 (1 to 5)
Not given	43	6 (4 to 7)	17	6 (4 to 10)	23	9 (6 to 13)	3	1 (0 to 3)

participants having the lowest prevalence of hypertension (5%) compared with West Hiri (22%) and Asaro (22%) (p<0.001). Higher percentages of elevated cholesterol (24%) and HbA1c (34%) were observed among West Hiri participants compared with Asaro and Karkar.

# **DISCUSSION**

The results from our study provide baseline prevalence of NCD risk factors in three sites in PNG. Combined with earlier data from Asaro and Karkar sites, there is evidence of an increase in some key NCD risk factors; however, there is substantial variation among the three communities due to demographic and socioeconomic differences. The NCD risk appears greatest in the periurban site of West Hiri, relative to the rural sites of Asaro and Karkar Island. Similar rural-urban differences have been seen in other PI nations such as Fiji and Western Samoa. The NCDs. The Previous studies found non-Austronesian populations to be less susceptible to developing diabetes and other NCDs. The Asaro population of non-Austronesian origin, however, recorded the highest central

obesity and prehypertension prevalence, indicating a rural population at very high risk of developing CVDs. West Hiri, an Austronesian population, as expected, had a higher prevalence of CVD and DMT2 risk factors. Karkar Island, a mixed Austronesian and non-Austronesian population, had low prevalence of some risk factors such as overweight and obesity, hypertension and elevated HbA1c levels. It also recorded the highest prevalence of tobacco smoking, insufficient physical activity and low HDL-C levels, indicating an increased risk for developing NCDs.

This is the first NCD study in West Hiri and having a diet low in vegetables compared with Asaro and Karkar Island reflects limited subsistence farming. However, more participants are in paid employment with regular income, which may explain the comparatively high alcohol and cigarette use and a diet high in sugar, salt and animal protein. Its close proximity to Port Moresby has resulted in a longer exposure to modernisation and the consequent increased risk of developing DMT2 and other NCDs. 9 32 52 This study provides evidence of an



Table 2 Study participants' self-reported food consumption in a typical week by iHDSS. Values are in numbers and percentages (95% CI)

	Over		West n=26		Asaro n=254		Kark n=25	ar Island 2	
Food consumption	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	p Value*
Root vegetables >5 days/ week†	503	65 (62 to 69)	46	17 (13 to 22)	211	83 (78 to 88)	245	98 (94 to 99)	<0.001
Greens >5 days/ week†	451	58 (54 to 62)	36	14 (10 to 18)	168	66 (60 to 72)	247	98 (95 to 99)	<0.001
Fruits >5 days/week <sup>†</sup>	97	13 (10 to 15)	64	24 (19 to 30)	33	13 (9 to 18)	0	0 (0 to 1)	<0.001
Fresh protein 5 days/ week†	216	28 (25 to 31)	128	48 (42 to 54)	4	2 (0.4 to 4)	84	33 (28 to 40)	<0.001
Canned protein 5 days/week†	181	23 (21 to 27)	138	52 (46 to 58)	26	10 (7 to 15)	17	7 (4 to 11)	<0.001
Teaspoon sugar >6 tsp daily	132	17 (15 to 20)	53	20 (15 to 25)	51	20 (15 to 26)	28	11 (8 to 16)	0.026
Sugary drinks 3+ days/week‡	43	6 (4 to 7)	34	13 (9 to 17)	9	4 (2 to 7)	0	0 (0 to 1)	<0.001
Purchased fried food >5 days/week†	18	2 (1 to 4)	4	2 (0 to 4)	14	6 (3 to 9)	0	0 (0 to 1)	<0.001
Home fried food >5 days/week†	151	20 (17 to 23)	41	16 (11 to 20)	109	43 (37 to 49)	1	0.4 (0 to 2)	<0.001
Stock cube 7 days/ week§	5	1 (0 to 2)	2	1 (0.1 to 2.7)	1	0 (0 to 2)	2	1 (0 to 3)	0.377
Salt directly on food 7 days/week§	361	47 (43 to 50)	162	61 (55 to 67)	144	57 (50 to 63)	55	22 (17 to 27)	<0.001

<sup>\*</sup>p Values were obtained by Pearson's  $\chi^2$ test and Fisher's exact test where appropriate, †Consumed for at least 5 days in a typical week, ‡Consumption of soft drink for at least 3 days in a typical week, §Consumption for 7 days of the week. iHDSS, integrated Health and Demographic Surveillance Sites.

existing high prevalence of NCD risk factors in the West Hiri population. The NCD risk factor burden is expected to increase further, especially with the socioeconomic transition occurring in this population, which may be accelerated due to its Austronesian ancestry and close proximity to PNG's fastest growing city, and through the steep increase in local disposable incomes (via salaries, wages and royalty payments from the gas project).

The prevalence of daily tobacco smoking in our study (41%) is far higher than the 26.3% prevalence reported in the 2009/2010 national Household Income and Expenditure Survey (HIES), <sup>55</sup> yet consistent with the 43.7% and 47.7% in the 2007/2008 PNG STEPS and Global Youth Tobacco Survey, respectively. <sup>36 56</sup> Our findings confirm that tobacco smoking rates have been high for a long period. There are even higher prevalences of current tobacco smokers in other Pacific countries, some of which were very high as in Kiribati, Wallis and Futuna, Tokelau and Fiji. <sup>57</sup> As tobacco smoking increases the risk of developing CVDs and other NCDs, <sup>58 59</sup> our findings suggest public health efforts are needed to identify appropriate measures to reduce the consumption of both manufactured and home-grown tobacco. Increasing tobacco tax has reduced consumption

of manufactured tobacco elsewhere, <sup>60</sup> but may not be effective in populations where home-grown tobacco is widely used. Accordingly, in addition to WHO's 'Best Buy' interventions, <sup>61</sup> public awareness campaigns highlighting the harmful effects of smoking, inclusive of home-grown tobacco, are required throughout PNG.

The prevalence of betel nut chewing was highest in the two coastal communities, where it is grown, compared with the highlands community of Asaro, and this is similar to a 1968 study which showed very high prevalence of betel nut chewing in two coastal communities, compared with a highlands community whose betel nut use was far lower. 62 The overall prevalence of betel nut chewing is higher than the 2009/2010 national HIES,<sup>55</sup> but supports the 2007/2008 STEPS<sup>36</sup> prevalence. Even reported prevalences from other countries as Taiwan and Malaysian Borneo were lower than the findings from our study.<sup>63</sup> Chewing of betel nut has been associated with oral cancer, elevated glucose and increased risk of CVDs. 64-67 It is deeply embedded into PNG's social and cultural traditions and is prevalent across the country, 36 55 62 even among pregnant women. 68 Therefore, it will be important to monitor the impacts of this

table 5 study participarity seri-reported diagricoses of notificable diseases and fish factors by in 1000. Values are notificable for contages (90.70 cm)	ים אבוויים	חסוומל	diaginoses of the		ui iicabie	diseases allu lis	ומכוחום די	y II IDOO	values ale IIul	ווטפו א	ם הפוכם	11ayes (33 70 O	
	Overall	lle.		West Hiri	Hiri		Asaro			Karkar	Karkar Island		
Diseases	z	c	% (95% CI)	z	u	% (95% CI)	z	u	% (95% CI)	z	L	% (95% CI)	p Value*
Stroke	692	8	0.4 (0 to 1)	266	က	1 (0 to 3)	253	0	0 (0 to 1)	250	0	0 (0 to 1)	0.111
Heart disease	767	4	1 (0 to 1)	265	4	2 (0 to 4)	252	0	0 (0 to 1)	250	0	0 (0 to 1)	0.037
Diabetes mellitus T2	771	2	1 (0 to 2)	266	2	2 (1 to 4)	254	0	0 (0 to 1)	251	0	0 (0 to 1)	0.012
Chronic lung disease/ asthma	772	16	2 (1 to 3)	266	10	4 (2 to 7)	254	4	2 (0 to 4)	252	2	1 (0 to 3)	0.065
Hypercholesterolaemia	692	-	0.1 (0 to 1)	264	-	0.4 (0, 2.)	254	0	0 (0 to 1)	251	0	0 (0 to 1)	1.00
Hypertension	767	56	3 (2 to 5)	266	20	8 (5 to 11)	250	2	2 (1 to 5)	251	-	0.4 (0 to 2)	<0.001
Cancer	771	2	0.3 (0 to 1)	266	-	0.4 (0 to 2)	254	0	0 (0 to 1)	251	-	0.4 (1 to 2)	0.772

\*p Value obtained by performing Fisher's exact test. iHDSS, integrated Health and Demographic Surveillance Sites.

habit and provide appropriate public health messages combined with stronger and sustainable measures to reduce its use. A betel nut ban has recently been implemented in Port Moresby<sup>69</sup> and a robust evaluation should be conducted in order to establish the public health benefit, if any, from this intervention.

Our study found a higher prevalence of current alcohol use among the periurban West Hiri (43%) relative to rural Asaro (22%) and Karkar (7%) and this may be due to the high employment rate and increased availability of cash among the West Hiri population. A similar pattern reported in 1977 saw an increased alcohol use among men with high social status in the two communities of Karkar Island and Lufa.<sup>70</sup> However, our results showed a similar 'binge drinking' pattern (low frequency, high volume consumption) across all sites which was a common finding among Pacific youths in New Zealand.<sup>71</sup> The national HIES (9%) and STEPS (15%) survey reported lower prevalence of alcohol consumption than our findings. Studies from neighbouring PI nations, however, recorded much higher alcohol consumption rates.<sup>57</sup> This binge drinking pattern in PNG previously reported to contribute to law and order problems affecting one's health, work and family.<sup>72</sup> As such, adoption of appropriate measures such as WHO's 'best buys'61 is needed to control excessive alcohol consumption in the country which may include increased tax in the manufacture and sale of alcohol, ban on alcohol advertisement and awareness through education.

The findings from our study reveal that one in every three participants reported stress. However, there were significant differences across the sites, where Karkar participants reported the least percentage of stress relative to West Hiri and Asaro. Karkar participants live on an island further away from the nearest town compared with West Hiri and Asaro who are closer to towns, relying more on cash economy for the purchase of goods and services. A recent study identified two major sources of stress among PNG women: one is economic and supply instability and the other is stress associated with relationships with others.<sup>73</sup> Changes associated with urbanisation are likely to affect both. Further studies are needed to investigate the degree of stress as well as identify the stress vulnerable groups faced in PNG.

Our study found a higher prevalence of physical inactivity in both Karkar Island and West Hiri, compared with Asaro. The overall prevalence of insufficient physical activity is higher than that reported in the STEPS survey. PNG has one of the lowest prevalences of physical inactivity in the Pacific region where rates greater than 50% in both women and men have been reported. To Culturally appropriate interventions are needed to promote sufficient physical activity across PNG to help reduce the risk of developing NCDs. With towns and urban areas becoming unsafe for walking or jogging, most people commute only by vehicle, to a need for urban planners to incorporate safety plans to enable the use of public space for leisure activities.

tick factors         N         n         % (65% C)I         N		Overall	all a		West	ΞΞ		Asaro			Karka	Karkar Island		۵
tobasco         268         43         44 (44 to 53)         155         64         41 (34 to 50)         171         85         50 (42 to 57)         90         62         95 (34 to 73)         97         62         71 (51 to 50)         70	NCD risk factors	z	u	% (95% CI)	z	u	% (95% CI)	z	u	% (95% CI)	z	u	% (95% CI)	Value*
1	Daily tobacco smokers†	526	253	48 (44 to 53)	155	64	41 (34 to 50)	171	85	50 (42 to 57)	200	104	52 (45 to 59)	0.170
7.8         8.2         2.9 (24 to 35)         8.4         1.7         2.0 (12 to 30)         81         2.8         1.8         4.2         37 (28 to 47)         7.6         8.8         8.8         9.0         <	Male	248	171	69 (63 to 75)	71	47	66 (54 to 77)	06	62	69 (58 to 78)	87	62	71 (61 to 80)	0.588
be of to be occupated.  27   12 (8 to 17)   21   35 (23 to 48)   56   8 (3 to 17)   59   8 (3 to 17)   50   6 (3 to 17)   50   50 (3 to 10)   50	Female	278	82	29 (24 to 35)	84	17	20 (12 to 30)	81	23	28 (19 to 40)	113	42	37 (28 to 47)	0.035
Proposition state of gasterine and sisted signatured state and sisted cigarettes         27         12 (8 to 17)         21         35 (23 to 48)         6         8 (3 to 17)         9         0 (0 to 4)           space (spear)         42         19 (14 to 25)         39         65 (52 to 77)         2         3 (10 9)         1         1 (10 to 6)           space (spear)         42         19 (14 to 25)         15         6 (35 to 77)         17         2         3 (10 9)         1         1 (10 to 6)           space (brus)         42         18         18         6 (35 to 72)         17         36         8 (30 to 92)         17         36         4 (35 to 12)         17         36         3 (10 to 6)         17	Types of tobacco smoked		224		09			92			88			
Mittened dark seace (parally lives)  155 69 (58 to 70)  150 0 (10 to 6)  1	Manufactured filtered cigarette		27	12 (8 to 17)		21	35 (23 to 48)		9	8 (3 to 17)		0	0 (0 to 4)	<0.001
megrown size by seed b	Unfiltered dark tobacco (spear/ mutrus)		42	19 (14 to 25)		39	65 (52 to 77)		2	3 (0 to 9)		-	1 (0 to 6)	<0.001
sunptionth         523         118         23 (19 to 26)         152         66         43 (35 to 52)         171         38         22 (16 to 29)         200         14         7 (4 to 12)           sunptionth         sile         36         38 (35 to 45)         71         49         69 (57 to 79)         90         33         37 (27 to 47)         87         7 (4 to 12)           sile         25         22         8 (5 to 12)         81         17         21 (13 to 31)         81         5         6 (2 to 14)         113         90         14         7 (4 to 12)           sile         35         3 (1 to 6)         0         0         0 (0 to 4)         5         8 (3 to 18)         17         1 (13 to 31)         81         7         1 (2 to 23)         1 (2 to 23)         1 (2 to 23)         1 (2 to 23)         1 (2 to 24)         1 (2 to 24)         2 (2 to 14)         1 (2 to 24)         2 (2 to 14)         1 (2 to 24)         3 (2 to 13)         3 (2 to 14)         4 (2 to 14)<	Home-grown tobacco (brus)		155	69 (58 to 70)		0	0 (0 to 6)		89	89 (80 to 95)		87	99 (94 to 100)	<0.001
lie         248         96         39 (33 to 45)         71         49         69 (57 to 79)         90         33         37 (27 to 47)         87         14         16 (9 to 26)           male         275         22         8 (5 to 12)         81         7         21 (13 to 31)         81         5         6 (2 to 14)         113         0         0 (0 to 3)           12 months         13         2         3 (1 to 6)         3         3         2         4         4         6 (3 to 14)         113         0         0 (0 to 4)           sily         3         4 (2 to 8)         3         4 (2 to 8)         3         4         4 (2 to 8)         3         4         4 (2 to 8)         4         4 (2 to 23)         4         4 (2 to 8)         4         4 (2 to 23)         4         4 (2 to 14)         5         8 (3 to 18)         7         1 (2 to 23)         7         4 (3 to 14)         5         8 (3 to 18)         7         4 (3 to 10)         4         4 (3 to 10)         4         4 (3 to 16)         4 (3 to 16)         4 (3 to 16)         4 (3	Current alcohol consumption‡	523	118	23 (19 to 26)	152	99	43 (35 to 52)	171	38	22 (16 to 29)	200	41	7 (4 to 12)	0.001
male         275         22         8 (5 to 12)         81         17         21 (13 to 31)         81         5         6 (2 to 14)         113         0         0 (0 to 3)           12 months         5         3 (1 to 6)         0         0 (0 to 4)         5         8 (3 to 18)         6         0 (0 to 10)           14 sys/week         7         4 (2 to 8)         0         0 (0 to 4)         7         12 (5 to 23)         0         0 (0 to 10)           4 days/week         12         6 (3 to 11)         6         7 (3 to 14)         5         8 (3 to 18)         1         0 (0 to 10)           4 days/week         12         6 (3 to 11)         6         7 (3 to 14)         5         8 (3 to 18)         1         3 (to 15)           4 days/week         12         6 (3 to 11)         6         7 (3 to 14)         5         8 (3 to 18)         1         1 (5 to 3)           3 days/month         58         3 (4 to 58)         43         48 (3 to 59)         31         5 (3 to 69)         41 (3 to 50)           3 chands         50         3 (4 to 50)         43         48 (3 to 59)         44         5 (4 to 69)         44 (3 to 69)         44 (3 to 69)           3 chands         3 (3	Male	248	96	39 (33 to 45)	71	49	69 (57 to 79)	06	33	37 (27 to 47)	87	14	16 (9 to 26)	0.002
12 months   185   1 to 6)   2   3 (1 to 6)   3   3   4   4   4   2 to 8)   3   4   4   4   4   3 (3 to 6)   3   4   3 (3 to 6)   3   3 (3 to 6)   3	Female	275	22	8 (5 to 12)	81	17	21 (13 to 31)	81	2	6 (2 to 14)	113	0	0 (0 to 3)	0.004
lily         5         3 (1 to 6)         0         0 (10 to 4)         5         8 (3 to 18)         0         0 (10 to 4)         7         12 (5 to 23)         0         0 (10 to 10)           4 days/week         1         4 (2 to 8)         0         0 (10 to 4)         7         12 (5 to 23)         0         0 (10 to 10)           4 days/week         1         4 (2 to 8)         0         0 (10 to 4)         7         12 (5 to 23)         0         0 (10 to 10)           3 days/month         58         31 (25 to 39)         40         45 (34 to 56)         12         2 (11 to 32)         1         1         3 (10 to 10)           10 sthandouth         58         103         45 (34 to 56)         43         48 (38 to 59)         12         2 (11 to 32)         1         2         17 (10 to 10)           10 mith         10 mith         245         179         145         145         94 (80 to 99)         168         93         55 (47 to 63)         85         148 (10 to 90)         149         149         141 (10 to 90)         149         141 (10 to 90)         141         140 (10 to 90)         141         141 (10 to 90)         141         141 (10 to 90)         141         141 (10 to 90)         141         1	Alcohol frequency past 12 months	185			88			09			36			
6 days/week         7         4 (2 to 8)         0         0 (0 to 4)         7         12 (5 to 23)         0         0 (0 to 10)           4 days/week         12         6 (3 to 11)         6         7 (3 to 14)         5         8 (3 to 18)         1         3 (10 to 15)           3 days/month         58         31 (25 to 39)         49         45 (34 to 56)         7         31         52 (38 to 65)         7         8         17 (6 to 33)           ss than once a systhm once a point of the systhm once a point of the systhm once a systhm once a system once a systhm o	Daily		2	3 (1 to 6)		0	0 (0 to 4)		2	8 (3 to 18)		0	0 (0 to 10)	0.023
4 days/week         12         6 (3 to 11)         6         7 (3 to 14)         5         8 (3 to 18)         1         3 (0 to 15)           3 days/month         58         31 (25 to 39)         40         45 (34 to 56)         12         20 (11 to 32)         6         17 (6 to 33)           ss than once a sthan once a state and set a state a st	5-6 days/week		7	4 (2 to 8)		0	0 (0 to 4)		7	12 (5 to 23)		0	0 (0 to 10)	0.004
3 days/month         58         31 (25 to 39)         40         45 (34 to 56)         12         20 (11 to 32)         6         17 (6 to 33)           ss than once a nuth         103         55 (48 to 63)         43         48 (38 to 59)         31         52 (38 to 65)         29         81 (64 to 92)           nuth         245         176 (70 to 78)         155         145         94 (89 to 97)         168         93         55 (47 to 63)         85         63         74 (63 to 81)           sle         245         179         73 (67 to 78)         71         64         90 (81 to 96)         79         41         52 (40 to 63)         112         86 (82 to 93)         93         84         90 (83 to 96)         148         145         128         88 (82 to 93)         93         84         90 (83 to 96)         148         145         96 (90 to 99)         79         41         52 (40 to 63)         148         145         96 (90 to 99)         79         41         52 (40 to 63)         148         145         96 (90 to 99)         79         41         52 (40 to 63)         148         145         96 (90 to 99)         79         41         52 (40 to 63)         148         148         148         90 (83 to 96)         148 <td>1-4 days/week</td> <td></td> <td>12</td> <td>6 (3 to 11)</td> <td></td> <td>9</td> <td>7 (3 to 14)</td> <td></td> <td>2</td> <td>8 (3 to 18)</td> <td></td> <td>-</td> <td>3 (0 to 15)</td> <td>0.513</td>	1-4 days/week		12	6 (3 to 11)		9	7 (3 to 14)		2	8 (3 to 18)		-	3 (0 to 15)	0.513
sst than once a fig. st that once a loss than once a loss that the loss than once a loss than once a loss than once a loss th	1-3 days/month		28	31 (25 to 39)		40	45 (34 to 56)		12	20 (11 to 32)		9	17 (6 to 33)	0.004
ving betel nutfs         520         386         74 (70 to 78)         155         145         94 (89 to 97)         168         93         55 (47 to 63)         197         148         75 (68 to 81)           ale         245         179         73 (67 to 79)         71         64         90 (81 to 96)         79         41         52 (40 to 63)         112         85         74 (63 to 83)           male         275         207         75 (70 to 80)         84         81 (82 to 93)         93         84         90 (83 to 96)         148         145         76 (67 to 83)           Inut with betel         386         357         92 (89 to 95)         145         128         88 (82 to 93)         93         84         90 (83 to 96)         148         145         98 (94 to 100)           and slaked         5         71         246         32 (29 to 35)         266         122         46 (40 to 52)         254         112         44 (38 to 56)         117         5         117         5         20 to 8)           sle         360         115         33 (28 to 38)         114         49         43 (34 to 56)         124         41 (32 to 50)         135         7         5 (2 to 10)	Less than once a month		103	55 (48 to 63)		43	48 (38 to 59)		31	52 (38 to 65)		29	81 (64 to 92)	0.016
sile         245         179         73 (67 to 79)         71         64         90 (81 to 96)         89         52         58 (47 to 69)         85         63         74 (63 to 83)           male         275         207         75 (70 to 80)         84         81         96 (90 to 99)         79         41         52 (40 to 63)         112         85         76 (67 to 83)           nut with betal         386         357         92 (89 to 95)         145         128         88 (82 to 93)         93         84         90 (83 to 96)         148         145         98 (94 to 100)           and slaked         36         771         246         32 (29 to 35)         266         122         46 (40 to 52)         254         112         44 (38 to 50)         252         12         5 (2 to 8)           sile         360         115         33 (28 to 38)         114         49         43 (34 to 53)         12         41 (32 to 50)         135         7         5 (2 to 10)	Chewing betel nut§	520	386	74 (70 to 78)	155	145	94 (89 to 97)	168	93	55 (47 to 63)	197	148	75 (68 to 81)	<0.001
male         275         207         75 (70 to 80)         84         81         96 (90 to 99)         79         41         52 (40 to 63)         112         85         76 (67 to 83)           Inut with betel 386         357         92 (89 to 95)         145         128         88 (82 to 93)         93         84         90 (83 to 96)         148         145         98 (94 to 100)           sand slaked         35         256 to 35         266         122         46 (40 to 52)         254         112         44 (38 to 50)         252         12         5 (2 to 8)           sle         360         115         33 (28 to 38)         114         49         43 (34 to 53)         130         61         47 (38 to 56)         117         5         4 (1 to 10)           male         411         131         31 (26 to 35)         152         73         48 (40 to 56)         124         51         41 (32 to 50)         135         7         5 (2 to 10)	Male	245	179	73 (67 to 79)	71	64	90 (81 to 96)	89	25	58 (47 to 69)	82	63	74 (63 to 83)	<0.001
Inut with betel 386 357 92 (89 to 95) 145 128 88 (82 to 93) 93 84 90 (83 to 96) 148 145 98 (94 to 100) and slaked.  Stand slak	Female	275	207	75 (70 to 80)	84	81	96 (90 to 99)	62	41	52 (40 to 63)	112	85	76 (67 to 83)	<0.001
771 246 32 (29 to 35) 266 122 46 (40 to 52) 254 112 44 (38 to 50) 255 12 5 (2 to 8) 360 115 33 (28 to 38) 114 49 43 (34 to 53) 130 61 47 (38 to 56) 117 5 4 (1 to 10) ale 411 131 31 (26 to 35) 152 73 48 (40 to 56) 124 51 41 (32 to 50) 135 7 5 (2 to 10)	Betel nut with betel bean and slaked ime	386	357	92 (89 to 95)	145	128	88 (82 to 93)	93	84	90 (83 to 96)	148	145	98 (94 to 100)	0.012
360 115 33 (28 to 38) 114 49 43 (34 to 53) 130 61 47 (38 to 56) 117 5 4 (1 to 10) 411 131 31 (26 to 35) 152 73 48 (40 to 56) 124 51 41 (32 to 50) 135 7 5 (2 to 10)	Stress	771	246	32 (29 to 35)	266	122	46 (40 to 52)	254	112	44 (38 to 50)	252	12	5 (2 to 8)	<0.001
411 131 31 (26 to 35) 152 73 48 (40 to 56) 124 51 41 (32 to 50) 135 7 5 (2 to 10)	Male	360	115	33 (28 to 38)	114	49	43 (34 to 53)	130	61	47 (38 to 56)	117	5	4 (1 to 10)	<0.001
	Female	411	131	31 (26 to 35)	152	73	48 (40 to 56)	124	21		135	7	5 (2 to 10)	<0.0>

Continued

ı	ď	
ı	=	
ı	ŧ	
ı	2	
ı	Č	
ı		

N         n         % (95% CJ)         N         n         n         % (95% CJ)         n         n         n         n         n         n         n         n         n         n         n         n		Overall	all le		West H	Hiri		Asaro			Karka	Karkar Island		۵
	NCD risk factors	z	_	% (95% CI)	z	L	% (95% CI)	z	u	% (95% CI)	z	u	% (95% CI)	Value*
1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	Insufficient physical activity¶		101	20 (17 to 24)	169	39	23 (17 to 30)	186	12	6 (4 to 11)	149	50	34 (26 to 42)	<0.001
1(46)	Male	233	37	16 (11 to 21)	92	14	18 (10 to 29)	94	5	5 (2 to 12)	63	18	29 (18 to 41)	<0.001
	Female	271	64	24 (19 to 29)	93	25	27 (18 to 37)	92	7	8 (3 to 15)	86	32	37 (27 to 48)	<0.001
Key/         Tof7         144         19 (16 to 22)         264         65         25 (20 to 30)         252         59         23 (18 to 29)           356         67         19 (15 to 23)         112         32         29 (20 to 38)         128         29         23 (18 to 23)           411         77         19 (15 to 23)         152         33         22 (18 to 28)         124         30         24 (17 to 33)           767         82         11 (9 to 13)         264         59         22 (18 to 28)         124         30         24 (17 to 33)           767         82         16 (3 to 9)         112         15         13 (8 to 21)         124         13         10 (6 to 17)           7         758         20         6 (3 to 9)         112         44         29 (22 to 37)         124         13         10 (6 to 17)           8         514         62 (57 to 67)         112         50         45 (35 to 54)         125         30 (86 to 39)           9         738         123 + 17.5         264         125.7 ± 19.8         222         126         250 (90 to 60)           10         738         123         24 (45 to 50)         124         29 (20 to 60)         125	Mean (SD) BMI (kg/ m²)	792		23.9±5.7	264		26±7.1	252		24.0±4.4	251		21.5±4.0	<0.001
356         67         19 (15 to 23)         112         32         29 (20 to 38)         128         29         23 (16 to 31)           411         77         19 (15 to 23)         152         33         22 (15 to 29)         124         30         24 (17 to 33)           356         20         (3 to 9)         112         15         13 (8 to 21)         128         3         2 (15 to 10)           411         62         (15 to 19)         152         44         29 (22 to 37)         124         13         10 (6 to 17)           R         758         514         68 (64 to 71)         264         138         52 (46 to 58)         255         90 (86 to 93)           A         758         514         68 (64 to 71)         264         138         52 (46 to 58)         255         90 (86 to 93)           A         758         514         68 (64 to 71)         264         138         52 (46 to 58)         255         90 (86 to 93)           A         758         514         68 (45 to 71)         152         88         58 (50 to 60)         122         78 449.7           A         738         75.3±10.9         264         77±12.4         222         78 449.7	Overweight (BMI ≥25–29.9kg/ m²)	767	144	19 (16 to 22)	264	65	25 (20 to 30)	252	29	23 (18 to 29)	251	20	8 (5 to 12)	<0.001
411 77 19 (15 to 23) 152 33 22 (15 to 29) 124 30 24 (17 to 33)  767 82 11 (9 to 13) 264 59 22 (18 to 28) 252 16 6 (4 to 10)  356 20 6 (3 to 9) 112 15 13 (8 to 21) 128 3 2 (0.5 to 7)  411 62 15 (12 to 19) 152 44 29 (22 to 37) 124 13 10 (6 to 17)  R 758 514 68 (64 to 71) 264 138 52 (46 to 58) 250 225 90 (86 to 93)  351 218 62 (57 to 67) 112 50 45 (35 to 54) 122 100 82 (74 to 88)  407 296 73 (88 to 77) 152 88 58 (50 to 66) 122 100 82 (74 to 88)  738 123 175 264 120 46 (39 to 52) 222 123 55 (42 to 62)  738 339 46 (42 to 50) 264 120 46 (39 to 52) 222 123 55 (42 to 62)  738 339 46 (42 to 50) 264 120 46 (39 to 52) 222 123 55 (42 to 62)  738 118 16 (13 to 19) 264 58 22 (17 to 28) 222 48 22 (16 to 28)  738 4 65 19 (15 to 23) 112 32 29 (20 to 38) 115 28 24 (17 to 33)  738 534 65 19 (15 to 23) 112 32 29 (20 to 38) 115 28 24 (17 to 33)  738 738 738 738 738 738 738 738 738 738	Male	356	29	19 (15 to 23)	112	32	29 (20 to 38)	128	53	23 (16 to 31)	116	9	5 (2 to 11)	<0.001
767 82 11(9 to 13) 264 59 22 (18 to 28) 255 16 6 (4 to 10) 356 20 6 (3 to 9) 112 15 13 (8 to 21) 128 3 2 (0.5 to 7) 411 62 15 (12 to 19) 152 44 29 (22 to 37) 124 13 10 (6 to 17)  R 758 514 68 (64 to 71) 264 138 52 (46 to 58) 250 225 90 (86 to 93) 407 296 73 (68 to 77) 152 88 58 (50 to 66) 122 100 82 (74 to 88)  P 738 129 46 (42 to 50) 264 120 46 (39 to 52) 222 123 55 (42 to 62)  934 150 38 (33 to 43) 152 55 36 (29 to 44) 107 56 52 (16 to 28)  149 55 (10 to 52) 112 55 36 (29 to 44) 107 56 52 (16 to 28)  153 4 65 19 (15 to 23) 112 32 29 (20 to 38) 115 28 24 (17 to 33)  150 10 10 10 10 10 10 10 10 10 10 10 10 10	Female	411	77	19 (15 to 23)	152	33	22 (15 to 29)	124	30	24 (17 to 33)	135	14	10 (6 to 17)	0.009
356 20 6(3 to 9) 112 15 13 (8 to 21) 128 3 2 (0.5 to 7)  411 62 15(12 to 19) 152 44 29(22 to 37) 124 13 10 (6 to 17)  R 758 0.91±0.09 264 0.88±0.12 250 0.94±0.08  758 514 68 (64 to 71) 264 138 52 (46 to 58) 250 225 90 (86 to 93)  407 296 73 (88 to 77) 152 88 58 (50 to 66) 122 100 82 (74 to 88)  738 128 62 (57 to 67) 112 50 45 (35 to 54) 128 125 90 (86 to 93)  738 75.3±10.9 264 120 46 (39 to 52) 222 123 55 (42 to 62)  738 75.3±10.9 264 120 46 (39 to 52) 222 123 55 (42 to 62)  738 75.3±10.9 264 120 46 (39 to 52) 222 123 55 (42 to 62)  738 118 16 (13 to 19) 264 58 22 (17 to 28) 222 48 22 (16 to 28)  738 118 16 (13 to 19) 264 58 22 (17 to 28) 222 48 22 (16 to 28)  738 14 85 13 (10 to 17) 152 26 17 (14 to 24) 107 20 19 (12 to 27)  738 148 65 19 (15 to 23) 112 25 50 (17 to 28) 215 22 48 22 (16 to 28)  739 4 53 13 (10 to 17) 152 26 17 (14 to 24) 107 20 19 (12 to 27)	Obesity (BMI ≥30 kg/m²)	792	82	11 (9 to 13)	264	29	22 (18 to 28)	252	16	6 (4 to 10)	251	7	3 (1 to 6)	<0.001
H 758	Male	356	20	6 (3 to 9)	112	15	13 (8 to 21)	128	က	2 (0.5 to 7)	116	2	2 (0.2 to 6)	<0.001
R 758   514   68 (64 to 71)   264   138   52 (46 to 58)   250   225   90 (86 to 93)   250   251   252   25	Female	411	62	15 (12 to 19)	152	44	29 (22 to 37)	124	13	10 (6 to 17)	135	2	4 (1 to 8)	<0.001
758 514 68 (64 to 71) 264 138 52 (46 to 58) 250 225 90 (86 to 93) 351 218 62 (57 to 67) 112 50 45 (35 to 54) 128 125 98 (93 to 100) 407 296 73 (68 to 77) 152 88 58 (50 to 66) 122 100 82 (74 to 88) 2738 75.3±10.9 264 120 46 (39 to 52) 222 123 55 (42 to 62) 374 189 55 (50 to 60) 112 65 58 (48 to 67) 115 67 58 (49 to 67) 394 150 38 (33 to 43) 152 55 36 (29 to 44) 107 56 52 (16 to 28) 394 65 19 (15 to 23) 112 32 29 (217 to 28) 222 48 22 (16 to 28) 394 65 19 (15 to 23) 112 32 29 (20 to 38) 115 28 24 (17 to 33) 394 53 13 (10 to 17) 152 26 17 (14 to 24) 107 20 19 (12 to 27)	Mean (SD) WHR	758		$0.91\pm0.09$	264		0.88±0.12	250		0.94±0.08	244		0.90±0.06	<0.001
351         218         62 (57 to 67)         112         50         45 (35 to 54)         128         125         98 (93 to 100)           407         296         73 (68 to 77)         152         88         58 (50 to 66)         122         100         82 (74 to 88)           738         123±17.5         264         125.7±19.8         222         126.7±16.8         126.7±16.8           738         339         46 (42 to 50)         264         120         46 (39 to 52)         222         123         78.4±9.7           344         189         55 (50 to 60)         112         65         58 (48 to 67)         115         67         58 (49 to 67)           344         189         55 (50 to 60)         112         65         36 (29 to 44)         107         56         52 (42 to 62)           738         118         16 (13 to 19)         264         58         22 (17 to 28)         22         48         22 (16 to 28)           344         65         19 (15 to 23)         112         32         29 (20 to 38)         115         28         24 (17 to 33)           344         65         19 (15 to 23)         12         29 (20 to 38)         115         28         24 (17 to 23) <td>Central obesity (WHR, M≥0.9/ F≥0.85)</td> <td>758</td> <td>514</td> <td>68 (64 to 71)</td> <td>264</td> <td>138</td> <td>52 (46 to 58)</td> <td>250</td> <td>225</td> <td>90 (86 to 93)</td> <td>244</td> <td>151</td> <td>62 (56 to 68)</td> <td>&lt;0.001</td>	Central obesity (WHR, M≥0.9/ F≥0.85)	758	514	68 (64 to 71)	264	138	52 (46 to 58)	250	225	90 (86 to 93)	244	151	62 (56 to 68)	<0.001
407         296         73 (68 to 77)         152         88         58 (50 to 66)         122         100         82 (74 to 88)           738         123±17.5         264         125.7±19.8         222         126.7±16.8           738         339         46 (42 to 50)         264         120         46 (39 to 52)         123         78.4±9.7           344         189         55 (50 to 60)         112         65         58 (48 to 67)         115         67         58 (49 to 62)           344         189         55 (50 to 60)         112         65         58 (48 to 67)         115         67         58 (49 to 67)           344         189         55 (50 to 60)         112         65         36 (29 to 44)         107         56         52 (42 to 62)           738         118         16 (13 to 19)         264         58         22 (17 to 28)         222         48         22 (16 to 28)           344         65         19 (15 to 23)         112         32         29 (20 to 38)         115         28         24 (17 to 33)           344         65         13 (10 to 17)         152         26         17 (14 to 24)         107         20         19 (12 to 27)	Male	351	218	62 (57 to 67)	112	20	45 (35 to 54)	128	125	98 (93 to 100)	11	43	39 (30 to 48)	<0.001
738         123±17.5         264         125.7±19.8         222         126.7±16.8           738         339         46 (42 to 50)         264         120         46 (39 to 52)         123         55 (42 to 62)           344         189         55 (50 to 60)         112         65         58 (48 to 67)         115         67         58 (49 to 67)           394         150         38 (33 to 43)         152         55         36 (29 to 44)         107         56         52 (42 to 62)           738         118         16 (13 to 19)         264         58         22 (17 to 28)         222         48         22 (16 to 28)           344         65         19 (15 to 23)         112         32         29 (20 to 38)         115         28         24 (17 to 33)           344         65         19 (15 to 23)         112         32         29 (20 to 38)         115         28         24 (17 to 33)           344         65         13 (10 to 17)         152         26         17 (14 to 24)         107         20         19 (12 to 27)           394         53         13 (10 to 17)         152         26         17 (14 to 24)         107         20         19 (12 to 27)	Female	407	296	73 (68 to 77)	152	88	58 (50 to 66)	122	100	82 (74 to 88)	133	108	81 (74 to 87)	<0.001
738         75.3±10.9         264         77±12.4         222         78.4±9.7           738         339         46 (42 to 50)         264         120         46 (39 to 52)         123         55 (42 to 62)           344         189         55 (50 to 60)         112         65         58 (48 to 67)         115         67         58 (49 to 67)           394         150         38 (33 to 43)         152         55         36 (29 to 44)         107         56         52 (42 to 62)           738         118         16 (13 to 19)         264         58         22 (17 to 28)         222         48         22 (16 to 28)           344         65         19 (15 to 23)         112         32         29 (20 to 38)         115         28         24 (17 to 33)           344         65         13 (10 to 17)         152         26         17 (14 to 24)         107         20         19 (12 to 27)           708         4.6±1.8         258         5.0±1.8         218         4.7±1.7	Mean (SD) SBP (mm Hg)	738		123±17.5	264		125.7±19.8	222		126.7±16.8	252		116.8±13.3	<0.001
738         339         46 (42 to 50)         264         120         46 (39 to 52)         222         123         55 (42 to 62)           344         189         55 (50 to 60)         112         65         58 (48 to 67)         115         67         58 (49 to 67)           394         150         38 (33 to 43)         152         55         36 (29 to 44)         107         56         52 (42 to 62)           738         118         16 (13 to 19)         264         58         22 (17 to 28)         222         48         22 (16 to 28)           344         65         19 (15 to 23)         112         32         29 (20 to 38)         115         28         24 (17 to 33)           394         53         13 (10 to 17)         152         26         17 (14 to 24)         107         20         19 (12 to 27)           708         4.6±1.8         258         5.0±1.8         218         4.7±1.7	Mean (SD) DBP (mm Hg)	738		75.3±10.9	264		77±12.4	222		78.4±9.7	252		70.7±8.5	<0.001
344       189       55 (50 to 60)       112       65       58 (48 to 67)       115       67       58 (49 to 67)         394       150       38 (33 to 43)       152       55       36 (29 to 44)       107       56       52 (42 to 62)         738       118       16 (13 to 19)       264       58       22 (17 to 28)       222       48       22 (16 to 28)         344       65       19 (15 to 23)       112       32       29 (20 to 38)       115       28       24 (17 to 33)         394       53       13 (10 to 17)       152       26       17 (14 to 24)       107       20       19 (12 to 27)         708       4.6±1.8       258       5.0±1.8       218       4.7±1.7	Prehypertension**	738	339	46 (42 to 50)	264	120	46 (39 to 52)	222	123	55 (42 to 62)	252	96	38 (32 to 44)	0.001
394         150         38 (33 to 43)         152         55         36 (29 to 44)         107         56         52 (42 to 62)           738         118         16 (13 to 19)         264         58         22 (17 to 28)         222         48         22 (16 to 28)           344         65         19 (15 to 23)         112         32         29 (20 to 38)         115         28         24 (17 to 33)           394         53         13 (10 to 17)         152         26         17 (14 to 24)         107         20         19 (12 to 27)           708         4.6±1.8         258         5.0±1.8         218         4.7±1.7	Male	344	189	55 (50 to 60)	112	65	58 (48 to 67)	115	29	58 (49 to 67)	117	22	49 (39 to 58)	0.25
738         118         16 (13 to 19)         264         58         22 (17 to 28)         222         48         22 (16 to 28)           344         65         19 (15 to 23)         112         32         29 (20 to 38)         115         28         24 (17 to 33)           394         53         13 (10 to 17)         152         26         17 (14 to 24)         107         20         19 (12 to 27)           708         4.6±1.8         258         5.0±1.8         218         4.7±1.7	Female	394	150	38 (33 to 43)	152	22	36 (29 to 44)	107	26	52 (42 to 62)	135	39	29 (21 to 37)	0.001
344       65       19 (15 to 23)       112       32       29 (20 to 38)       115       28       24 (17 to 33)         394       53       13 (10 to 17)       152       26       17 (14 to 24)       107       20       19 (12 to 27)         708       4.6±1.8       258       5.0±1.8       218       4.7±1.7	Hypertension (≥140/90 mm Hg)	738	118	16 (13 to 19)	264	28	22 (17 to 28)	222	48	22 (16 to 28)	252	12	5 (3 to 8)	<0.001
394 53 13 (10 to 17) 152 26 17 (14 to 24) 107 20 19 (12 to 27) 708 4.6±1.8 258 5.0±1.8 218 4.7±1.7	Male	344	65	19 (15 to 23)	112	32	29 (20 to 38)	115	28	24 (17 to 33)	117	2	4 (1 to 10)	<0.001
708 4.6±1.8 258 5.0±1.8 218 4.7±1.7	Female	394	53	13 (10 to 17)	152	26	17 (14 to 24)	107	20	19 (12 to 27)	135	7	5 (2 to 10)	<0.001
CNOIESTE/OI (MMOI/L)	Mean (SD) cholesterol (mmol/L)			4.6±1.8	258		5.0±1.8	218		4.7±1.7	232		4.2±1.7	<0.001



Table 4 Continued													
	Overall	   		West	ΞΞ		Asaro			Karka	Karkar Island		۵
NCD risk factors	z	u	% (95% CI)	z	u	% (95% CI)	z	u	% (95% CI)	z	u	% (95% CI)	Value*
Elevated cholesterol 708 (>6.2 mmol/L)	708	123	17 (15 to 20)	258	61	24 (19 to 29)	218	35	16 (11 to 22)	232	27	12 (8 to 17)	0.002
Male	321	20	16 (12 to 20)	108	22	20 (13 to 29)	108	18	17 (10 to 25)	105	10	10 (5 to 17)	0.086
Female	387	73	19 (15 to 23)	150	39	26 (19 to 34)	110	17	15 (9 to 24)	127	17	13 (8 to 21)	0.016
Mean (SD) HDL-C (mmol/L)	602		1.2±0.6	258		1.3±0.5	218		1.1±0.5	233		1.0±0.6	<0.001
Low HDL-C††	602	388	55 (51 to 58)	258	116	45 (39 to 51)	218	127	58 (51 to 65)	233	145	62 (56 to 68)	<0.001
Male	322	142	44 (39 to 50)	108	33	31 (22 to 40)	108	49	45 (36 to 55)	106	09	57 (47 to 66)	0.001
Female	387	246	64 (59 to 68)	150	83	55 (47 to 63)	110	78	71 (61 to 79)	127	85	67 (58 to 75)	0.023
Mean (SD) HbA1c	712		5.4±0.8	253		5.7±1.2	220		5.3±0.3	239		5.2±0.4	<0.001
Prediabetes HbA1c (≥5.7%–6.4%)	712	107	15 (13 to 18)	253	92	26 (20 to 32)	220	25	11 (8 to 16)	239	17	7 (4 to 11)	<0.001
Male	323	41	13 (9 to 17)	107	20	19 (12 to 27)	109	13	12 (7 to 20)	107	80	7 (3 to 14)	0.052
Female	386	99	17 (13 to 21)	146	45	31 (23 to 39)	111	12	11 (6 to 18)	132	0	7 (3 to 13)	<0.001
DMT2 HbA1c (≥6.5%)	712	24	3 (2 to 5)	253	22	9 (6 to 13)	220	0	0 (0 to 2)	239	7	1 (0 to 3)	<0.001
Male	323	∞	2 (1 to 5)	107	œ	7 (3 to 14)	109	0	0 (0 to 3)	107	0	0 (0 to 3)	<0.001
Female	386	16	4 (2 to 7)	146	14	10 (5 to 16)	11	0	0 (0 to 3)	132	7	2 (0.2 to 5)	<0.001

p Values were obtained by Pearson's  $\chi^2$  test and Fisher's exact test where appropriate for categorical variables and one-way ANOVA for continuous variables, †Current tobacco smoking on a daily basis, ‡Consumption of alcohol within last 30 days.

§Chewed betel nut within last 30 days, ¶Vigorous physical activity <75 min and moderate physical activity <150 min/week, \*\*Prehypertension=SBP>120-139.9 mm Hg and/or DBP 80-89 mm 19, ††Low HDL-C=<1 mmol/L men and ≤1.3 mmol/L women.

ANOVA, analysis of variance; BMI, body mass index; DBP, diastolic blood pressure; DMT2, diabetes mellitus type 2; HbA1c, haemoglobin A1c; HDL-C, high-density lipoprotein-cholesterol; HDSS, integrated Health and Demographic Surveillance Sites; NCD, non-communicable disease; SBP, systolic blood pressure; WHR, waist-to-hip ratio.

Our results showed a higher prevalence of overweight and obesity in periurban West Hiri relative to rural Asaro and Karkar Island. Norgan in 1995 reported overweight and obesity prevalence in Karkar and Lufa communities was less than 10%, 75 which is lower than our findings. In addition, the overall obesity prevalence (11%) in our study is higher than that reported in the PNG STEPS survey. 36 Although the West Hiri obesity rates (22%) are comparable to that reported for Port Moresby residents (21%), it is lower than that in some neighbouring Pacific Islands. 35 57 Despite the low prevalence of obesity, especially in Asaro and Karkar Island, our results showed very high prevalence of central obesity (waist-to-hip ratio) across all sites, but more so in Asaro. Central obesity, based on waist-to-hip ratio, has been reported to substantially increase the risk of CVDs and is a preferred measure of obesity for predicting CVD and all-cause deaths. 76 77 The high prevalence of central obesity in Asaro indicates a different propensity for fat distribution to West Hiri. This finding further indicates the standard BMI thresholds may not be suitable for use in PNG, as has also been suggested for other ethnic groups in the Asia Pacific region. 46 Some countries have introduced taxes on unhealthy food and beverages to reduce their consumption. <sup>78</sup> Health promotion via media, education in schools and workplaces as that in New Zealand<sup>79</sup> may also help reduce overweight and obesity prevalence. PNG may need to consider adopting such initiatives to help reduce and control the availability and sales of high sugar, salt and fat content foods in the country.

Other CVD risk factors, such as elevated BP and hyperlipidaemia, were higher across the three sites in our study compared with the earlier PNG STEPS survey. High rates of prehypertension (55%) in the Asaro population are concerning as studies conducted between the 1950s and 1980s in the highlands population showed low levels of elevated BP. 80-82 According to previous studies in Asaro, the prevalence of hypertension was 14 83 lower than our findings (22%). Similarly, in the 1960s-1980s hypertension was absent or very low in Karkar as elsewhere in the country. 14 84-86 However, our results showed increased prevalence of both prehypertension (38%) and hypertension (5%) among the Karkar population. Over the last two decades, hypertension has been recorded at very high levels in other parts of the country, such as the Purari Delta, Manus and urban Port Moresby. 13 29

Inter-regional differences in NCD risks have been previously observed for hypercholesterolaemia. Some parts of the country inclusive of Asaro and rural Central Province recorded zero or low prevalence of hypercholesterolaemia from the late 1980s to early 1990s, <sup>17 87 88</sup> yet very high in certain populations such as urban Port Moresby and group of male miners in Bougainville. <sup>17 23 89</sup> The prevalence of hypercholesterolaemia (24%) in our periurban West Hiri population was slightly lower than that of urban Port Moresby, although a lower cut-off (≥5.2 mmol/L) was used in the latter study. Our results combined with these previous studies suggest an urgent need for interventions

to control CVD risk factors across all populations of PNG. In addition to WHO's 'best buys,'<sup>61</sup> and a country appropriate adaptation of the Green Prescription,<sup>90</sup> enabling health education programmes to promote activity and healthy lifestyle in schools and communities would be beneficial for PNG.

Previous studies have reported a variable prevalence of DMT2 in parts of PNG. According to studies conducted in the 1980s-1990s, DMT2 was absent or existed at very low prevalence in many parts of PNG including Karkar Island and Asaro communities. 33 34 54 DMT2 prevalences in these communities have remained low over a long period of time and our findings are consistent with the earlier studies; however, prediabetes data from our study may suggest this is changing. Indeed, studies conducted in Koki, in urban Port Moresby, Wanigela village in Central Province and residents of Port Moresby between the 1970s and 2000 reported very high prevalences of DMT2. <sup>16</sup> <sup>18</sup> <sup>31</sup> <sup>32</sup> Based on genetics and longer exposure to modernisation, it is not surprising that West Hiri population had a higher prevalence of both prediabetes (26%) and DMT2 (9%) than Asaro and Karkar. Together with previous studies, our findings indicate limited change in DMT2 in recent history but continued marked disparity between populations, although the percentage of adults with elevated HbA1c across sites should be of significant concern. Control measures should include restrictions on imported high-sugar and fat content foods as well as the use of mass media and other education and public awareness raising activities.

# **STRENGTHS AND LIMITATIONS**

The study had a number of strengths and limitations. Strengths include an up-to-date prevalence of NCD risk factors in three sites at different stages of social and economic development; and the collection of NCD risk factor data during the early stages of a huge gas development project which provides a baseline for future longitudinal studies to monitor NCDs and risk factors. The limitations are as follows: First, this was a cross-sectional study and provides a snapshot of the risk and disease burden at a particular moment in time. Second, the study was conducted in only three locations across PNG and is therefore not nationally representative. Third, the full sample size was not achieved and younger people were undersampled, which could have led to an overestimation of NCD risk factor burden. Fourth, the study relied on the participants' self-report for some measures, possibly resulting in recall bias (eg, self-reported 7-day food consumption). Fifth, biological samples were not collected from all participants therefore interpretation of results was limited only to those with biological samples.

# **CONCLUSION**

Although not nationally representative, our study is suggestive of a socioeconomic and nutrition transition being under way in all three sites, especially in periurban



West Hiri, which had a higher NCD risk factor burden compared with the rural sites. However, some risk factors were common across sites, suggesting these populations are at heightened risk of developing CVDs. Few participants had received an NCD diagnosis despite the high prevalence of NCD risk factors, suggesting that current NCD screening and prevention as well as treatment services are inadequate in the sites taking part in this study. Training on NCDs and their risk factors as well as appropriate lifestyle interventions need to be incorporated into existing health training curriculum. Such training would facilitate appropriate screening, monitoring and control of NCDs at the primary healthcare setting. In addition, facilities need to be provided with the basic equipment/tools for screening. This calls for an urgent need to mobilise appropriate and multisectoral preventive interventions and upskill health services. Regular monitoring of these populations would provide up-to-date information and feedback on the effectiveness of any interventions for the emerging NCD epidemic in PNG.

### **Author affiliations**

<sup>1</sup>Melbourne School of Population & Global Health, University of Melbourne, Melbourne, Victoria, Australia

<sup>2</sup>PNG Institute of Medical Research, Goroka, Papua New Guinea <sup>3</sup>School of Public Health, The University of Queensland, Herston, Brisbane, Queensland, Australia

<sup>4</sup>Queensland Centre for Mental Health Research, The Park Centre for Mental Health Treatment, Research and Education, Wacol, Queensland, Australia

<sup>5</sup>Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

<sup>6</sup>School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea

<sup>7</sup>School of Population Health, The University of Auckland, Auckland, New Zealand <sup>8</sup>Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

<sup>9</sup>Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan

<sup>10</sup>Nossal Institute for Global Health, University of Melbourne, Melbourne, Victoria, Australia

<sup>11</sup>Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK

**Correction notice** This paper has been amended since it was published Online First. Owing to a scripting error, some of the publisher names in the references were replaced with 'BMJ Publishing Group'. This only affected the full text version, not the PDF. We have since corrected these errors and the correct publishers have been inserted into the references.

Acknowledgements The authors wish to thank all research participants, Provincial Government, church health authorities and community representatives in the respective sites. The authors are grateful to the dedicated NCD Study field and laboratory staff members. The authors also acknowledge the PNGIMR for providing the administrative and technical support to conduct this study. Lastly, we acknowledge the financial support via an unrestricted grant provided by PNG ExxonMobil to conduct this survey in the three sites. The governance and management of the study was completely independent from the funders.

**Contributors** RS, CB, IR, GM, AM, MU, IHK, JP, GV, HG, SP and PR were responsible for study design. PR, JP, GV, HG and SP helped conduct the study and were responsible for data collection. PR conducted the data analysis and was responsible for drafting the manuscript. JP, RS, CB, AM, MU, HG, BO and BM critically revised the manuscript. The final draft was approved by all authors.

Competing interests None declared.

Patient consent All study participants signed a consent form prior to being recruited into the study.

**Ethics approval** PNG Institute of Medical Research Institutional Review Board and PNG Medical Research Advisory Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

**Data sharing statement** Requests for data access should be directed to the corresponding author and will be granted subject to approval by the Medical Research Advisory Council of Papua New Guinea.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

### **REFERENCES**

- WHO, ed. Global status report on noncommunicable diseases 2010. Geneva, Switzerland: World Health Organization, 2011:176.
- WHO. ed. Global status report on noncommunicable disease 2014. Geneva, Switzerland: WHO, 2014:298.
- Collaborators GMaC. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease study 2013. Lancet 2015;385:117–71.
- National Statistical Office PNG. Final Figures. Papua New Guinea. National Population and Housing Census 2011. Port Moresby: National Statistical Office, 2013.
- National Statistical Office PnG. Papua New Guinea Demographic and Health Survey 2006. Port Moresby: National Statistical Office, 2009.
- Group WB. Data. World Bank Country and Lending Groups 2015. http://data.worldbank.org/about/country-and-lending-groups (cited Nov 2015).
- Tasman A. PNG LNG Economic Impact Study. An assessment of the direct and indirect impacts of the proposed PNG LNG project on the economy of Papua New Guinean. 2009.
- Amuna P, Zotor FB. Epidemiological and nutrition transition in developing countries: impact on human health and development. *Proc Nutr Soc* 2008;67:82–90.
- Zimmet P, Globalization ZP. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? *J Intern Med* 2000;247:301–10.
- WHO. Papua New Guinea: WHO Statistical Profile. Papua New Guinea: WHO, 2015.
- 11. Vines AP. An epidemiological sample survey of the highlands, mainland and islands regions of the Territory of Papua and New Guinea. An epidemiological sample survey of the highlands, mainland and islands regions of the Territory of Papua and New Guinea. 1970.
- 12. King H, Collins AM. A modernity score for individuals in Melanesian society. *P N G Med J* 1989;32:11–22.
- Ulijaszek SJ. Hypertension among adults of the Purari delta of the Gulf Province, Papua New Guinea. P N G Med J 1998;41:65–71.
- King H, Collins V, King LF, et al. Blood pressure, hypertension and other cardiovascular risk factors in six communities in Papua New Guinea, 1985-1986. P N G Med J 1994;37:100-9.
- Schall JI. Sex differences in the response of blood pressure to modernization. American Journal of Human Biology 1995;7:159–72.
- Dowse GK, Spark RA, Mavo B, et al. Extraordinary prevalence of non-insulin-dependent diabetes mellitus and bimodal plasma glucose distribution in the Wanigela people of Papua New Guinea. Med J Aust 1994;160:767–74.
- Hodge AM, Dowse GK, Erasmus RT, et al. Serum lipids and modernization in coastal and highland Papua New Guinea. Am J Epidemiol 1996;144:1129–42.
- Benjamin AL. Community screening for diabetes in the National Capital District, Papua New Guinea: is betelnut chewing a risk factor for diabetes? P N G Med J 2001;44:101–7.
- Kende M. Superiority of traditional village diet and lifestyle in minimizing cardiovascular disease risk in Papua New Guineans. P N G Med J 2001;44:135–50.
- Saweri W. The rocky road from roots to rice: a review of the changing food and nutrition situation in Papua New Guinea. P N G Med J 2001;44:151–63.
- Yamauchi T, Umezaki M, Ohtsuka R. Influence of urbanisation on physical activity and dietary changes in Huli-speaking population: a comparative study of village dwellers and migrants in urban settlements. *Br J Nutr* 2001;85:65–73.



- Ulijaszek SJ. Socio-economic factors associated with physique of adults of the Purari delta of the Gulf Province, Papua New Guinea. Ann Hum Biol 2003;30:316–28.
- Iser DJ, Avera K. Has westernization influenced serum cholesterol levels in Bougainvillian males? P N G Med J 1993;36:311–5.
- H X. Stagnant stunting rate despite rapid economic growth in Papua New Guinea-factors correlated with malnutrition among children under five. 2015.
- King SE, Nicholas Mascie-Taylor CG. Nutritional status of children from Papua New Guinea: associations with socioeconomic factors. Am J Hum Biol 2002;14:659–68.
- Gibson J. Nutritional status of Papua New Guinea's population and its determinants. Papua New Guinea Food and Nutrition 2000 Conference, PNG University of Technology;2000;
- DeBoer MD, Lima AA, Oría RB, et al. Early childhood growth failure and the developmental origins of adult disease: do enteric infections and malnutrition increase risk for the metabolic syndrome? Nutr Rev 2012;70:642–53.
- 28. Health PNGNDo. *Health sector review 2001-2009 Report*. Port Moresby: PNG National Department of Health, 2009.
- Benjamin A. Community screening for high blood pressure among adults in urban and rural Papua New Guinea. PNG Med J 2006;49:137–46.
- Kevau IH. Clinical documentation of twenty cases of acute myocardial infarction in Papua New Guineans. P N G Med J 1990;33:275–80.
- Patel M, Jamrozik K, Allen O, et al. A high prevalence of diabetes in a rural village in Papua New Guinea. Diabetes Res Clin Pract 1986;2:97–103.
- Martin FI, Wyatt GB, Griew AR, et al. Diabetes mellitus in urban and rural communities in Papua New Guinea. Studies of prevalence and plasma insulin. *Diabetologia* 1980;18:369–74.
- King H, Finch C, Koki G, et al. Glucose tolerance in Papua New Guinea: comparison of Austronesian and non-Austronesian communities of Karkar Island. Diabet Med 1991;8:481–8.
- King H, Finch C, Collins A, et al. Glucose tolerance in Papua New Guinea: ethnic differences, association with environmental and behavioural factors and the possible emergence of glucose intolerance in a highland community. Med J Aust 1989;151:204–10.
- Benjamin AL. Body size of Papua New Guineans: a comparison of the body mass index of adults in selected urban and rural areas of Papua New Guinea. P N G Med J 2007;50:163–71.
- National Department of Health P, HOPE Worldwide P, WHO. Papua New Guinea NCD Risk Factor STEPS Report. Port Moresby: National Department of Health, PNG, 2014.
- Gouda H, Vengiau G, Phuanukoonnon S, et al. Report of Partnership in Health Project (PiHP) 2011-2012. Report. PNG Institute of Medical Research, 2013.
- Pham B, Maraga S, Kumai J, et al. PNGIMR PiH progress report: Reporting period January - June 2015. PNG Institute of Medical Research. 2015
- WHO. STEPwise approach to noncommunicable disease risk factor surveillance (STEPS). http://www.who.int/chp/steps/instrument/en/.
- 40. Wurm SA. Linguistic prehistory in the New Guinea area. *J Hum Evol* 1983:12:25–35.
- 41. Dutton TE. The Hiri in History: Further aspects of long distance Motu trade in Central Papua. Australian National University, 1982.
- 42. Benediktsson K. Harvesting development: The construction of fresh food markets in Papua New Guinea. Denmark: NIAS Press, 2002.
- Boyce AJ, Harrison GA, Platt CM, et al. Migration and Genetic Diversity in an Island Population: Karkar, Papua New Guinea. Proceedings of the Royal Society B: Biological Sciences 1978;202:269–95.
- Kambuou R. Papua New Guinea: Country Report to the FAO International Technical Conference on Plant Genetic Resources. Country Report. Konedobu 1995.
- WHO. Global recommendations on physical activity for health. Geneva, Swtizerland: World Health Organization, 2010.
- Committee S. The Asia-Pacific perspective: Redefining obesity and its treatment. Australia Health Communications Australia 2000.
- Expert Consultation W. Waist Circumference and Waist-Hip Ratio Report of a WHO Expert Consultation 2008, Report. Geneva, Switzerland: WHO, 2011.
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52.
- Panel NE. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143.

- Lauer MS, Fontanarosa PB. Updated guidelines for cholesterol management. JAMA 2001;285:2508–9.
- American Diabetes Association. Standards of medical care in diabetes--2010. *Diabetes Care* 2010;33(Supplement 1):S11-61.
- Zimmet P, Taylor R, Ram P, et al. Prevalence of diabetes and impaired glucose tolerance in the biracial (Melanesian and Indian) population of Fiji: a rural-urban comparison. Am J Epidemiol 1983:118:673–88.
- Zimmet P, Faaiuso S, Ainuu J, et al. The prevalence of diabetes in the rural and urban Polynesian population of Western Samoa. *Diabetes* 1981;30:45–51.
- 54. King H, Heywood P, Zimmet P, et al. Glucose tolerance in a highland population in Papua New Guinea. *Diabetes Res* 1984;1:45–51.
- National Statistical Office P. 2009-2010 Papua New Guinea Household Income and Expenditure Survey. PNG National Statistical Office, 2013.
- Centers for Disease Control and Prevention. Population Survey -Global Youth Tobacco Survey (GYTS), 2007.
- Kessaram T, McKenzie J, Girin N, et al. Noncommunicable diseases and risk factors in adult populations of several Pacific Islands: results from the WHO STEPwise approach to surveillance. Aust N Z J Public Health 2015;39:336–43.
- Woodward M, Lam TH, Barzi F, et al. Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol 2005;34:1036–45.
- Martiniuk AL, Lee CM, Lam TH, et al. The fraction of ischaemic heart disease and stroke attributable to smoking in the WHO Western Pacific and South-East Asian regions. *Tob Control* 2006;15:181–8.
- Abascal W, Esteves E, Goja B, et al. Tobacco control campaign in Uruguay: a population-based trend analysis. Lancet 2012;380:1575–82.
- World Health Organization. From burden to "best busy": Reducing the economic impact of NCDs in low-and middle-income countries. Executive summary 2011. Geneva: WHO, 2011.
- Pindborg JJ, Barmes D, Roed-Petersen B. Epidemiology and histology of oral leukoplakia and leukoedema among Papuans and New Guineans. *Cancer* 1968;22:379–84.
- Gupta PC, Warnakulasuriya S. Global epidemiology of areca nut usage. Addict Biol 2002;7:77–83.
- Javed F, Bello Correra FO, Chotai M, et al. Systemic conditions associated with areca nut usage: a literature review. Scand J Public Health 2010:38:838–44.
- Thomas SJ, Bain CJ, Battistutta D, et al. Betel quid not containing tobacco and oral cancer: a report on a case-control study in Papua New Guinea and a meta-analysis of current evidence. Int J Cancer 2007;120:1318–23.
- 66. Tung TH, Chiu YH, Chen LS, et al. A population-based study of the association between areca nut chewing and type 2 diabetes mellitus in men (Keelung Community-based Integrated Screening programme No. 2). *Diabetologia* 2004;47:1776–81.
- Lin WY, Chiu TY, Lee LT, et al. Betel nut chewing is associated with increased risk of cardiovascular disease and all-cause mortality in Taiwanese men. Am J Clin Nutr 2008;87:1204–11.
- Ome-Kaius M, Unger HW, Singirok D, et al. Determining effects of areca (betel) nut chewing in a prospective cohort of pregnant women in Madang Province, Papua New Guinea. BMC Pregnancy Childbirth 2015;15:177.
- National Capital District Commission. National District Betelnut Control Law 2013: Port Moresby National Capital District Commission, 2013.
- Hornabrook RW, Serjeantson S, Stanhope JM. The relationship between socioeconomic status and health in two Papua New Guinean populations. *Hum Ecol* 1977;5:369–82.
- Teevale T, Robinson E, Duffy S, et al. Binge drinking and alcoholrelated behaviours amongst Pacific youth: a national survey of secondary school students. N Z Med J 2012;125:1352.
- 72. Marshall M. Alcohol consumption as a public health problem in Papua New Guinea. *Int J Addict* 1988;23:573–89.
- Hinton R, Earnest J, Stressors EJ. Stressors, coping, and social support among women in Papua New Guinea. *Qual Health Res* 2010;20:224–38.
- Vengiau G, Umezaki M, Phuanukoonnon S, et al. Diet and physical activity among migrant Bougainvilleans in Port Moresby, Papua New Guinea: association with anthropometric measures and blood pressure. Am J Hum Biol 2012;24:716–8.
- Norgan NG. Changes in patterns of growth and nutritional anthropometry in two rural modernizing Papua New Guinea communities. *Ann Hum Biol* 1995;22:491–513.
- Asia Pacific Cohort Studies Collaboration. Central obesity and risk of cardiovascular disease in the Asia Pacific Region. Asia Pac J Clin Nutr 2006;15:287–92.



- Welborn TA, Dhaliwal SS. Preferred clinical measures of central obesity for predicting mortality. Eur J Clin Nutr 2007;61:1373–9.
- Brownell KD, Frieden TR. Ounces of prevention---the public policy case for taxes on sugared beverages. N Engl J Med 2009;360:1805–8.
- 79. Sundborn G, Merriman T, Thornley S, et al. An 'End-Game' for sugar sweetened beverages? Pacific health dialog 2014;20:1.
- Whyte HM. Body fat and blood pressure of natives in New Guinea: reflections on essential hypertension. *Australas Ann Med* 1958;7:36–46.
- 81. Maddocks I. Blood pressures in Melanesians. *Med J Aust* 1967;1:1123.
- King H, Collins A, King LF, et al. Blood pressure in Papua New Guinea: a survey of two highland villages in the Asaro Valley. J Epidemiol Community Health 1985;39:215–9.
- 83. Carvalho JJ, Baruzzi RG, Howard PF, et al. Blood pressure in four remote populations in the INTERSALT Study. *Hypertension* 1989;14:238–46.
- 84. Boyce AJ, Attenborough RD, Harrison GA, et al. Variation in blood pressure in a New Guinea population. *Ann Hum Biol* 1978;5:313–9.

- Maddocks I, Vines AP. The influence of chronic infection on bloodpressure in New Guinea males. *Lancet* 1966;2:262–4.
- Stanhope J. Blood pressures of the Tinam-Aigram people, near Simbai, Madang District. PNG Med J 1968;11:60–1.
- Scrimgeour EM, McCall MG, Smith DE, et al. Levels of serum cholesterol, triglyceride, HDL-cholesterol, apoproteins A-I and B, and plasma glucose, and prevalence of diastolic hypertension and cigarette smoking in Papua New Guinea highlanders. *Pathology* 1989:21:46–50.
- Lindeberg S, Nilsson-Ehle P, Terént A, et al. Cardiovascular risk factors in a Melanesian population apparently free from stroke and ischaemic heart disease: the Kitava study. J Intern Med 1994;236:331–40.
- Erasmus RT, Sinha AK, Nathaniel K. Serum lipid concentrations in the Koki community: a preliminary report. P N G Med J 1993;36:306–10.
- Swinburn BA, Walter LG, Arroll B, et al. The green prescription study: a randomized controlled trial of written exercise advice provided by general practitioners. Am J Public Health 1998;88:288–91.



# Prevalence of non-communicable disease risk factors in three sites across Papua New Guinea: a cross-sectional study

Patricia Rarau, Gwendalyn Vengiau, Hebe Gouda, Suparat Phuanukoonon, Isi H Kevau, Chris Bullen, Robert Scragg, Ian Riley, Geoffrey Marks, Masahiro Umezaki, Ayako Morita, Brian Oldenburg, Barbara McPake and Justin Pulford

BMJ Glob Health 2017 2:

doi: 10.1136/bmjqh-2016-000221

Updated information and services can be found at: http://gh.bmj.com/content/2/2/e000221

These include:

This article cites 65 articles, 7 of which you can access for free at: References

http://gh.bmj.com/content/2/2/e000221#BIBL

This is an Open Access article distributed in accordance with the Creative **Open Access** 

Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work

non-commercially, and license their derivative works on different terms.

provided the original work is properly cited and the use is

non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Email alerting** service

Receive free email alerts when new articles cite this article. Sign up in the

box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Open access (436)

# **Notes**

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/